NeoGenomics announced the commercial availability of two new tests, expanding its cancer portfolio of innovative products. These include Neo Comprehensive- Heme Cancers, a next-generation sequencing panel with a comprehensive genomic profile of hematologic malignancies, and Early-stage Non-Small Cell Lung Cancer Panel, a therapy selection panel designed specifically for early-stage NSCLC patients.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on NEO:
